NVO

Novo Nordisk A/S (NVO)

Last Price$78.7(5.3%)
Market Cap$350.5B
LTM FCF to Net Income
71.2%
5Y avg
93.4%
Biotechnology industry median
83.9%
Stock quality & Intrinsic value

Novo Nordisk A/S FCF to Net Income

Annual
Quarterly
LTM
Industry median
Company stand-alone
NVO
Healthcare
0.0%20.0%40.0%60.0%80.0%100.0%Jan'06Jan'08Jan'10Jan'12Jan'14Jan'16Jan'18Jan'20Jan'2288.8%82.0%68.6%88.7%112.3%114.3%109.6%105.5%86.7%88.5%103.3%91.5%105.6%85.3%83.4%91.3%70.9%99.7%115.5%83.7%
Dec'04Dec'05Dec'06Dec'07Dec'08Dec'09Dec'10Dec'11Dec'12Dec'13Dec'14Dec'15Dec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23
FCF to Net Income
88.8%
82.0%
68.6%
88.7%
112.3%
114.3%
109.6%
105.5%
86.7%
88.5%
103.3%
91.5%
105.6%
85.3%
83.4%
91.3%
70.9%
99.7%
115.5%
83.7%
NVO
Key metrics and insights to make informed decisions.
View full analysis
Overvalued or undervalued?
Check the intrinsic value for NVO and see if it's the right time to invest.
Dive in

Novo Nordisk A/S (NVO) FCF to Net Income comparison analysis

NVO key stats

USD
DKK
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Crunching data... Almost there!

Discover more Stock Ideas

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%

Undervalued growth stocks

Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.

3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
Loved by
investors
worldwide
10K+
Investors use our platform
#1
Top value investing hub with all necessary tools
1K+
Experienced investors in our community
4.9
Average rating across all rating platforms

FAQ

1) What is Novo Nordisk A/S's FCF to Net Income?

As of today, Microsoft Corp's last 12-month FCF to Net Income is 71.2%, based on the financial report for Sep 30, 2024 (Q3 2024). The average annual FCF to Net Income for Novo Nordisk A/S have been 92.7% over the past three years, and 98.1% over the past five years.

2) Is Novo Nordisk A/S's FCF to Net Income Good?

As of today, Novo Nordisk A/S's FCF to Net Income is 71.2%, which is lower than industry median of 83.9%. It indicates that Novo Nordisk A/S's FCF to Net Income is Bad.

3) How does Novo Nordisk A/S's FCF to Net Income compare to its peers?

As of today, Novo Nordisk A/S's FCF to Net Income is 71.2%, which is lower than peer median of 76.7%. The list of peers includes RPRX, VRTX, BGNE, ARGX, UTHR, REGN, SMMT, INCY, ALNY, BNTX.